Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | TK2 | O00142 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261563 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL18512865 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL659090 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL16805336 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL15810727 | 1.00 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL28738894 | 0.92 | LMNA (0.46) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL23547665 | 0.91 | LMNA (0.37) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL21999057 | 0.91 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL23547707 | 0.91 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL21999226 | 0.91 | LMNA (0.47) | LMNAMTORALDH1A1THRBMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601656-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2025-08-20 | — | — | EP | claimed |
| WO-2024077351-A1 | MODIFIED OLIGONUCLEOTIDES | Pharmorage Pty Limited (AU) | 2024-04-18 | — | — | WO | claimed |
| EP-4247393-A1 | CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING | Aligos Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| WO-2022109129-A1 | CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-20220160748-A1 | CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING | ALIGOS THERAPEUTICS, INC. | 2022-05-26 | — | — | US | claimed |
| US-20090307805-A1 | ALTERNATIVE NUCLEOTIDES FOR IMPROVED TARGETED NUCLEOTIDE EXCHANGE | KEYGENE N.V | 2009-12-10 | — | — | US | claimed |
| EP-0813539-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050059815-A1 | Processes for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom | COOK PHILLIP DAN (US) | 2005-03-17 | — | — | US | claimed |
| US-20030050454-A1 | Process for the synthesis of 2' -O-substituted pyrimidines and oligomeric compounds therefrom | ISIS PHARMACEUTICALS, INC. | 2003-03-13 | — | — | US | claimed |
| US-5861493-A | ALKYLATING WITH ALCOHOL IN PRESENCE OF LEWIS ACID; PREPARING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-19 | — | — | US | claimed |
| US-5767270-A | PROTECTING EXOCYCLIC AMINO GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | claimed |
| EP-4720294-A2 | MODIFIED UNC13A OLIGONUCLEOTIDES | Quralis Corporation (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | disclosed |
| US-5861493-A | ALKYLATING WITH ALCOHOL IN PRESENCE OF LEWIS ACID; PREPARING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5767270-A | PROTECTING EXOCYCLIC AMINO GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-16 | — | — | US | disclosed |
| US-5760202-A | TREATING 2,2'-ANHYDROPYRIMIDINE NUCLEOSIDE WITH ALCOHOL AND LEWIS ACID | ISIS PHARMACEUTICALS, INC. (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0813539-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1997-12-29 | — | — | EP | disclosed |
| WO-1996027606-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND OLIGOMERIC COMPOUNDS THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | LMNA 3119/4885MTOR 1898/4885ALDH1A1 4286/4885 |
| US-20050059815-A1 | Processes for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom | NUDT1, DPYD, UMPS | LMNA 3765/4885MTOR 4149/4885ALDH1A1 842/4885 |
| US-20220160748-A1 | CONJUGATES OF S-ANTIGEN TRANSPORT INHIBITING OLIGONUCLEOTIDE POLYMERS HAVING ENHANCED LIVER TARGETING | HAVCR2, CD74, SLC10A1 | LMNA 4002/4885MTOR 4606/4885ALDH1A1 2760/4885 |
| US-20030050454-A1 | Process for the synthesis of 2' -O-substituted pyrimidines and oligomeric compounds therefrom | ATIC, TYMS, RRM2 | LMNA 3797/4885MTOR 4007/4885ALDH1A1 940/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | LMNA 240/4885MTOR 3099/4885ALDH1A1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.